



FOR IMMEDIATE RELEASE

Five Prime Therapeutics, Inc. Adds Key Leaders to Its Management Team

San Francisco, CA, October 15, 2009—Five Prime Therapeutics, Inc. today announced the appointment of three executives to its management team. Aron Knickerbocker joins as vice president business development, Marc Belsky as vice president finance and Laretta Cesario as vice president human resources.

“I am delighted to work with Aron, Marc and Laretta at FivePrime,” remarked Julia P. Gregory, president and chief executive officer. “It is a great tribute to our world class scientific foundation and business strategy that we attracted these high performance individuals to our organization. I look forward to their many contributions as we advance our company in development.”

Aron Knickerbocker brings substantial experience in business development, licensing and corporate development. Mr. Knickerbocker joins FivePrime from Genentech, Inc. where he most recently served as senior director, business development, leading Genentech’s oncology business development team and responsible for evaluating and negotiating strategic alliances. He has worked previously with Alza Corporation, where he managed licensing transactions as their director of commercial development, and held sales, market research, marketing, and corporate development positions at Amgen, Inc. He began his career in the biopharmaceutical industry in research as a scientist at Bristol-Myers Squibb. Aron received his B.A. degree in biology from Washington University in St. Louis, and his M.B.A. degree from the University of Michigan. Mr. Knickerbocker will lead FivePrime’s business development and licensing activities to accelerate advancement of its drug pipeline and continue to mine the company’s robust discovery platform for innovative biologics.

Marc Belsky brings extensive experience in finance, accounting, treasury and taxation. He joins FivePrime after serving as vice president and chief accounting officer for Cell Genesys, Inc. Previously, he was the chief financial officer at Active Aero Group and DataWave Systems, Inc. and held senior finance and banking positions at Michigan National Corporation. Mr. Belsky started his career as an auditor with Coopers & Lybrand, is a certified public accountant, a certified treasury professional, and received an M.B.A. from the University of Michigan and a B.S. in accounting from Wayne State University. At FivePrime, he will lead the company’s finance and accounting group.

Laretta Cesario brings significant experience in human resources, recently as vice president human resources with Affymetrix, Inc. where she transformed the HR function into a functionally differentiated team supported by advanced technologies. Prior to Affymetrix, she was formerly with Scios, Inc, Silicon Graphics, Inc., National Semiconductor Corporation and Syntex Corporation. Ms. Cesario received her B.S. in psychology from Loyola University. She will head FivePrime’s human resources group and provide strategic organizational initiatives within its innovative discovery and development environment.

About Five Prime Therapeutics, Inc.

Five Prime Therapeutics, Inc. is a clinical stage, privately-held company discovering and developing innovative protein and antibody therapeutics. Using its world-class biologics discovery platform, FivePrime is building a strong product pipeline in oncology, immunology and metabolic diseases. It has engineered a unique suite of technologies to comprehensively mine the entire extracellular human proteome- the complete collection of secreted proteins and receptors- to discover its therapeutic protein drugs and antibody targets. FivePrime is currently in Phase I with FP-1039 for solid tumors. Pharmaceutical partners include Johnson & Johnson's Centocor division and Pfizer, Inc. For more information, visit www.fiveprime.com.

For further information, contact:

Jennifer Pratt Mead

Five Prime Therapeutics, Inc.

415-365-5663

Jennifer.pratt@fiveprime.com

###